(1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid | 1139743-14-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid
• 英文别名: (1R,3S)-3-[(5-cyano-4-phenyl-1,3-thiazol-2-yl)carbamoyl]cyclopentane-1-carboxylic acid
• CAS: 1139743-14-8
• 化学式: C₁₇H₁₅N₃O₃S
• 分子量: 341.39
• InChiKey: MSZKZEFOAPULKG-NWDGAFQWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  131
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid 在 magnesium(II) chloride hexahydrate 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 1.5h， 以71%的产率得到magnesium (1R,3S)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylate
  参考文献：
  名称：

  [EN] AMINE SALT OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID
  [FR] SEL D'AMINE DE L'ACIDE (1R,3S)-3-(5-CYANO-4-PHÉNYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANECARBOXYLIQUE

  摘要：

  本发明涉及(1R,3S)-3-(5-氰基-4-苯基-1,3-噻唑-2-基)氨甲酰基)环戊烷羧酸的曲妥他明盐、制备该盐的方法、包含该盐的复合物和药物组合物以及它们的医药用途，特别是用于治疗或预防通过A1腺苷受体拮抗作用改善的疾病。

  公开号：

  WO2018162505A1

文献信息

• [EN] NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX COMPOSÉS COMME ANTAGONISTES DES RÉCEPTEURS A1 DE L'ADÉNOSINE
  申请人：PALOBIOFARMA SL

  公开号：WO2009044250A1

  公开（公告）日：2009-04-09

  This compounds correspond to the formula (I), where: R1 represents and aryl or heteroaryl group optionally substituted by one or more substituents selected from the group consisting of halogen atoms, straight or branched optionally substituted lower alkyl, cycloalkyl, hydroxy, straight or branched, optionally substituted lower alkoxy, cyano, or -CO2R', wherein R' represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group; R2 represents a group selected from: a) a straight or branched lower alkyl group substituted by one or more carboxylic groups (-COOH) and optionally substituted by one or more halogen atoms; b) a cycloalkyl group substituted by one or more carboxylic groups (-COOH) and optionally substituted by one or more halogen atoms; c) a straight or branched alkylcycloalkyl or cycloalkylalkyl group substituted by one or more carboxylic groups (-COOH) and optionally substituted by one or more halogen atoms. Formula (I).

  这些化合物对应于公式(I)，其中：R1代表芳基或杂环基，可选择地被一个或多个取代基所取代，所述取代基从卤素原子、直链或支链的可选择取代的低烷基、环烷基、羟基、直链或支链的可选择取代的低烷氧基、氰基或-CO2R'中选择，其中R'代表氢原子或直链或支链的可选择取代的低烷基；R2代表从以下选组中选择的基团：a）被一个或多个羧基（-COOH）取代的直链或支链低烷基，可选择地被一个或多个卤素原子取代；b）被一个或多个羧基（-COOH）取代的环烷基，可选择地被一个或多个卤素原子取代；c）被一个或多个羧基（-COOH）取代的直链或支链烷基环烷基或环烷基烷基，可选择地被一个或多个卤素原子取代。公式（I）。
• [EN] COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCABAMOYL)CYCLOPENTANE CARBOXYLIC ACID<br/>[FR] COCRISTAUX D'ACIDE (1R,3S)-3-(5-CYANO-4-PHÉNYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIQUE
  申请人：PALOBIOFARMA SL

  公开号：WO2021185748A1

  公开（公告）日：2021-09-23

  The present invention relates to the cocrystals of (1 R,3S)-3-(5-cyano-4-phenyl- 1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid, a process for obtaining said cocrystals, combination products and pharmaceutical compositions comprising said cocrystals and their medical uses, in particular for the treatment or prevention of diseases known to ameliorate by A1 adenosine receptor antagonism.

  本发明涉及(1R,3S)-3-(5-氰基-4-苯基-1,3-噻唑-2-基甲酰基)环戊烷羧酸的共晶体，以及获得该共晶体的方法，包含该共晶体的组合物和制备该共晶体的药物组合物以及其医学用途，特别是用于治疗或预防已知通过A1腺苷受体拮抗作用改善的疾病。
• NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS
  申请人：Gonzalez Lio Lyhen

  公开号：US20100311703A1

  公开（公告）日：2010-12-09

  This compounds correspond to the formula (I), where: R 1 represents and aryl or heteroaryl group optionally substituted by one or more substituents selected from the group consisting of halogen atoms, straight or branched optionally substituted lower alkyl, cycloalkyl, hydroxy, straight or branched, optionally substituted lower alkoxy, cyano, or —CO 2 R′, wherein R′ represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group; R 2 represents a group selected from: a) a straight or branched lower alkyl group substituted by one or more carboxylic groups (—COOH) and optionally substituted by one or more halogen atoms; b) a cycloalkyl group substituted by one or more carboxylic groups (—COOH) and optionally substituted by one or more halogen atoms; c) a straight or branched alkylcycloalkyl or cycloalkylalkyl group substituted by one or more carboxylic groups (—COOH) and optionally substituted by one or more halogen atoms. Formula (I).

  这些化合物对应于公式(I)，其中: R1代表芳基或杂环芳基，可选地被来自卤素原子、直链或支链、可选地被取代的低烷基、环烷基、羟基、直链或支链、可选地被取代的低烷氧基、氰基或-CO2R'中的一种或多种取代基所取代，其中R'代表氢原子或直链或支链、可选地被取代的低烷基; R2代表以下之一的基团: a)一个直链或支链的低烷基，其被一个或多个羧基(-COOH)取代，并可选地被一个或多个卤素原子取代; b)一个被一个或多个羧基(-COOH)取代，并可选地被一个或多个卤素原子取代的环烷基; c)一个被一个或多个羧基(-COOH)取代，并可选地被一个或多个卤素原子取代的直链或支链烷基环烷基或环烷基烷基。公式(I)。
• COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCABAMOYL)CYCLOPENTANE CARBOXYLIC ACID
  申请人：Palobiofarma, S.L.

  公开号：EP3882240A1

  公开（公告）日：2021-09-22

  The present invention relates to cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid with gentisic acid, urea and nicotinamide, a process for obtaining said cocrystals, combination products and pharmaceutical compositions comprising said cocrystals and their medical uses, in particular for the treatment or prevention of diseases known to ameliorate by A1 adenosine receptor antagonism. n to ameliorate by A 1 adenosine receptor antagonism.

  本发明涉及(1R,3S)-3-(5-氰基-4-苯基-1,3-噻唑-2-基氨基甲酰基)环戊烷羧酸与龙胆二酸、尿素和烟酰胺的共晶体、获得所述共晶体的工艺、包含所述共晶体的组合产品和药物组合物及其医疗用途，特别是用于治疗或预防已知可通过A1腺苷受体拮抗作用改善的疾病。A1 腺苷受体拮抗剂可改善的疾病。
• Amine salt of (1R, 3S)-3-(5-cyano-4-phenyl-1,3- thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid
  申请人：PALOBIOFARMA, S.L.

  公开号：US10583127B2

  公开（公告）日：2020-03-10

  The present invention relates to the tromethamine salt of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid, a process for obtaining said salt, combination products and pharmaceutical compositions comprising said salts and their medical uses, in particular for the treatment or prevention of diseases known to ameliorate by A1 adenosine receptor antagonism.

  本发明涉及(1R,3S)-3-(5-氰基-4-苯基-1,3-噻唑-2-基氨基甲酰基)环戊烷羧酸的三甲胺盐、获得所述盐的工艺、包含所述盐的组合产品和药物组合物及其医疗用途，特别是用于治疗或预防已知可通过A1腺苷受体拮抗作用改善的疾病。